VT Finance AG
BB MEDTECH AG emittiert Wandelanleihe
Ad-hoc-Meldung übermittelt durch die DGAP – ein Unternehmen der EquityStory AG.
Für den Inhalt der Meldung ist der Emittent verantwortlich.
——————————————————————————
Die BB MEDTECH AG, Schaffhausen, begibt unter der Federführung der Bank am
Bellevue AG und HVB Corporates & Markets eine Wandelanleihe über CHF
100-150 Mio. mit einer Laufzeit von 3 Jahren und einer
Pflichtwandlungskomponente. Der Coupon wird zwischen 4 1/2 – 5% betragen.
Den Aktionären der BB MEDTECH AG in der Schweiz sowie in Deutschland wird
ein Recht auf die Vorwegzeichnung der Wandelanleihe eingeräumt.
In Anbetracht der guten Wachstumsaussichten der Medizintechnologie-Branche
hat der Verwaltungsrat der BB MEDTECH AG beschlossen, das derzeitige
Momentum zu nutzen und der Gesellschaft über die Ausgabe einer teilweisen
Pflicht-Wandelanleihe neue Mittel zuzuführen. Die BB MEDTECH AG wird mit
den Mitteln zunächst bestehende Verbindlichkeiten zurückführen sowie
weitere Investitionen der BB MEDTECH AG finanzieren. Andererseits setzt der
Verwaltungsrat mit der Wandelanleihe sein Bestreben fort, neue
Investorengruppen anzusprechen.
Die BB MEDTECH AG emittiert eine teilweise Pflicht-Wandelanleihe mit einem
Emissionsvolumen von bis zu CHF 150 Mio. Dieser Betrag beinhaltet eine
Mehrzuteilungsoption von bis zu 15% der Wandelanleihen, die nicht durch
Ausübung des Bezugsrechtes bestehender Aktionäre gezeichnet wurden. Der
Coupon wird zwischen 4 ½ und 5% betragen. Der Wandelpreis liegt zwischen
15% und 20% über dem volumengewichteten Durchschnittskurs der Aktie am 22.
Februar 2006 an der SWX Swiss Exchange. Am Ende der Laufzeit von 3 Jahren
erfolgt eine Pflichtwandlung von bis zu 50% der ursprünglich ausgegebenen
Wandelanleihen in Aktien der BB MEDTECH AG. Die Lieferung erfolgt entweder
aus eigenen Aktien der BB MEDTECH AG oder aus bedingtem Kapital. Die
Zwangswandlung ist limitiert auf 50% des Nennwertes aller ursprünglich
ausgegebenen Wandelanleihen abzüglich der Summe der Nennwerte aller
Wandelanleihen, die bis zum 13. Februar 2009 gewandelt wurden.
Die Zeichnungsfrist läuft vom 13. bis 22. Februar 2006 (12.00 Uhr MEZ). Die
definitiven Konditionen der Wandelanleihe werden am 22. Februar 2006 nach
17.30 Uhr MEZ festgelegt, die Zuteilung erfolgt anschliessend. Die
provisorische Zulassung der Wandelanleihen zum Handel an der SWX ist ab dem
1. März 2006 vorgesehen, Lieferung und Zahlung erfolgt am 6. März 2006.
Den Aktionären der BB MEDTECH AG in der Schweiz sowie in Deutschland wird
vom 13. bis 21. Februar 2006 ein Recht auf die Vorwegzeichnung der
Wandelanleihe eingeräumt. Dabei berechtigen 106 BB MEDTECH AG-Aktien zum
Bezug einer Wandelanleihe von CHF 1 000 nominal gegen Zahlung des
Nominalwerts.
Die Wandelanleihe wird (mit Ausnahme des Vorwegzeichnungsrechts) in
Deutschland nur bei institutionellen Anlegern platziert.
Sales Restrictions
United States of America Sales Restrictions
The Offering consists of (i) a public offering of the Bonds in
Switzerland,and (ii) a private placement of the Bonds in certain other
jurisdictions.
The Bonds have not been and will not be registered under the U.S.
Securities Act of 1933, as amended (the ‘Securities Act’) or any state
securities laws and may not be offered, sold, delivered or transferred
within the United States or to, or for the account or benefit of, U.S.
persons except in certain transactions in accordance with Regulation S
under the Securities Act (‘Regulation S’) or pursuant to an exemption from,
or in a transaction not subject to, the registration requirements of the
Securities Act. Terms used in this paragraph have the meanings assigned to
them by Regulation S.
In addition, until 40 days after commencement of the offering, an offer or
sale of the Bonds within the United States by a dealer (whether or not
participating in the offering) may violate the requirements of the
Securities Act.
United Kingdom Sales Restrictions
(A) This document is only directed at and will only be provided to persons
having professional experience in matters relating to investments within
Article 19(4) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (‘Relevant Persons’). Any investment or investment
activity to which this document relates is available only to Relevant
Persons and will be engaged in only with Relevant Persons. Persons who do
not have professional experience in matters relating to investments should
not rely on this document. This offer is made to or directed only at
qualified investors for the purpose of section 85 of the Financial Services
and Markets Act 2000.
Each of the Managers has represented, warranted and agreed to comply with
the sales restriction in (A) above and furthermore that:
(B) it has complied and will comply with all applicable provisions of the
Financial Services and Markets Act 2000 (the ‘FSMA’) with respect to
anything done by it in relation to the Bonds in, from or otherwise
involving the United Kingdom; and
(C) it has only communicated or caused to be communicated and will only
communicate or cause to be communicated any invitation or inducement to
engage in investment activity (within the meaning of section 21 of the
FSMA) in connection with the issue or sale of any Bonds in circumstances in
which section 21(1) of the FSMA does not apply to the Issuer. As used
herein, ‘United Kingdom’ means the United Kingdom of Great Britain and
Northern Ireland.
German Sales Restrictions
The Bonds have not been and will not be registered under the securities
laws of Germany and the Prospectus has not been and will not be submitted
for approval to the German Federal Financial Services Supervisory Authority
(Bundesanstalt für Finanzdienstleistungsaufsicht – ‘BaFin’) or to any other
competent authority of any other member state of the European Economic Area
which has implemented the Prospectus Directive. Therefore, the Bonds may
not be offered to the public in Germany, except to legal entities which are
authorised or regulated to operate in the financial markets listed in
Section 2 No. 6 a) of the German Securities Prospectus Act
(Wertpapierprospektgesetz), or, if not so authorised or regulated, whose
corporate purpose is solely to invest in securities.
Italian Sales Restrictions
This document has not been filed with CONSOB, the Italian Securities
Commission, and no application has been or will be made to obtain an
authorisation from CONSOB for a public offering in Italy. Accordingly, any
investment or investment activity to which this document relates may not be
offered, sold or delivered, and neither this document nor any other offer
document may be distributed, in Italy except to qualified investors
(operatori qualificati), as defined in Article 31(2) of CONSOB Regulation
no. 11522 of 1 July, 1998, as amended (‘Regulation 11522’), and Article 100
of Legislative Decree no. 58 of 24 February, 1998, as amended (‘Decree No
58’), or in any other circumstances where an express exemption from
compliance with the solicitation restrictions provided by Decree No. 58 or
CONSOB Regulation No. 11971 of 14 May 1999, as amended, applies. Any offer,
sale or delivery of any investment or investment activity to which this
document relates or any distribution of copies of this document or any
other offer document in Italy must be:
(A) made by investment firms, banks or financial intermediaries permitted
to conduct such activities in Italy in accordance with Legislative Decree
No. 385 of 1 September 1993 (‘Decree No. 385’), Decree No. 58, Regulation
No. 11522 and any other applicable laws and regulations;
(B) in compliance with Article 129 of Decree No. 385 and the implementing
instructions of the Bank of Italy, pursuant to which the issue, trading or
placement of securities in Italy is subject to prior notification to the
Bank of Italy, unless an exemption, depending, inter alia, on the amount of
the issue and the characteristics of the securities, applies; and
(C) in compliance with any other applicable notification requirement or
limitation which may be imposed by CONSOB or the Bank of Italy.
The offering of Advance Subscription Rights is not addressed to holders of
the Shares of the Issuer which are resident in Italy and consequently any
offer to subscribe submitted directly or indirectly by holders of the
Shares which are resident in Italy shall not be accepted.
General Sales Restrictions
No action has been or will be taken in any jurisdiction other than
Switzerland by the Issuer or the Managers that would, or is intended to,
permit a public offering of the Bonds, or possession or distribution of the
Prospectus or any other offering material, in any country or jurisdiction
where action for that purpose is required. No offer has been made or will
be made where such offer would be illegal.
(c)DGAP 13.02.2006
—————————————————————————
Sprache: Deutsch
Emittent: BB MEDTECH AG
Vordergasse 3
CH – 8200 Schaffhausen Schweiz
Telefon: +41 44 267 67 07
Fax: +41 44 267 67 01
Email: carmen.valares@swissfirst.ch
WWW: www.bbmedtech.ch
ISIN: CH0000428661
WKN: 898194
Indizes:
Börsen: Geregelter Markt in Frankfurt; Freiverkehr in Berlin-Bremen,
Düsseldorf, Hamburg, München, Stuttgart; Auslandsbörse(n)
Zurich
Ende der Mitteilung DGAP News-Service
—————————————————————————
Latest News
Latest Reports
Upcoming Events
No Events found
Webcasts
No Webcasts found